ArticlemSphere2019
Identification of 4-Amino-Thieno[2,3-
Open access · goldAbstract read
In one paragraph
Article in mSphere, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Inhibitors of cytochromemBio · 2026Article
- 1,2,4-Triazole-Based First-in-Class Non-Nucleoside Inhibitors of the Bacterial Enzyme MraY.ACS bio & med chem Au · 2025Article
- Scaffold Hopping Strategy toward New 4‑Aminoquinazolines Active Against Extracellular and Intracellular.ACS medicinal chemistry letters · 2025Article
- New Triazolopyrimidines with Improved Activity againstACS medicinal chemistry letters · 2025Article
- Article
- Structural and mechanistic study of a novel inhibitor analogue ofnpj drug discovery · 2025Article
- An open-access dashboard to interrogate the genetic diversity of Mycobacterium tuberculosis clinical isolates.Scientific reports · 2024Article
- Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines TargetingACS infectious diseases · 2023Article
- Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis CytochromeAntimicrobial agents and chemotherapy · 2023Article
- Target Identification in Anti-Tuberculosis Drug Discovery.International journal of molecular sciences · 2023Review
- Molecular Mechanisms of MmpL3 Function and Inhibition.Microbial drug resistance (Larchmont, N.Y.) · 2023Review
- Design, Cytotoxicity and Antiproliferative Activity of 4-Amino-5-methyl-thieno[2,3-d]pyrimidine-6-carboxylates against MFC-7 and MDA-MB-231 Breast Cancer Cell Lines.Molecules (Basel, Switzerland) · 2022Article
- Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance inFrontiers in cellular and infection microbiology · 2022Review
- Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Structure guided generation of thieno[3,2-RSC medicinal chemistry · 2021Article
- SAR Analysis of Small Molecules Interfering with Energy-Metabolism inPharmaceuticals (Basel, Switzerland) · 2020Review
- Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?Frontiers in cellular and infection microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Gregory A HarrisonDepartment of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA.ORCID 0000-0002-6050-1312
Anne E Mayer BridwellDepartment of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Megh SinghCenter for World Health and Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
Keshav JayaramanDepartment of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Leslie A WeissDepartment of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Rachel L KinsellaDepartment of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Janessa S AnekeDepartment of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Kelly FlentieDepartment of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Miranda E ScheneDepartment of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Margaret GaggioliDepartment of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Samantha D SolomonDepartment of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Scott A WildmanUniversity of Wisconsin Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Marvin J MeyersCenter for World Health and Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
Christina L StallingsDepartment of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA stallings@wustl.edu.
Washington University in St. Louis · USSaint Louis University · USUniversity of Wisconsin–Madison · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MWashington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4MTRAINING PROGRAM IN CELLULAR AND MOLECULAR BIOLOGYT32GM007067 · NIGMS · WASHINGTON UNIVERSITY · PI TRUE-KROB, HEATHER L · 1985 to 2020
$20.4MOPPORTUNITIES IN GENOMICS RESEARCH: INCREASING DIVERSITY AND RETENTION IN STEMR25HG006687 · NHGRI · WASHINGTON UNIVERSITY · PI MITRA, ROBI D, SKEATH, JAMES BENJAMIN · 2012 to 2025
$4.1MChemical disarming of drug resistance in Mycobacterium tuberculosisR01AI134847 · NIAID · WASHINGTON UNIVERSITY · PI ALMQVIST, FREDRIK, STALLINGS, CHRISTINA LEIGH · 2018 to 2021
$2.7MTargeting a New Essential Virulence Mechanism in Drug-Resistant MycobacteriaR33AI111696 · NIAID · WASHINGTON UNIVERSITY · PI STALLINGS, CHRISTINA LEIGH · 2016 to 2018
$1.4MNCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA091842NHGRI NIH HHS R25 HG006687NIAID NIH HHS R01 AI134847NIAID NIH HHS R33 AI111696NIGMS NIH HHS T32 GM007067
Abstract
Antibiotic resistance is a global crisis that threatens our ability to treat bacterial infections, such as tuberculosis, caused by
Indexed as
Antibiotics, AntitubercularBacterial ProteinsDrug DiscoveryElectron Transport Complex IIIMicrobial Sensitivity TestsMutationMycobacterium tuberculosisPyrimidinesAntibiotics, AntitubercularBacterial ProteinsElectron Transport Complex IIIPyrimidinesantibioticCydABcytochromedrug discoveryMycobacterium tuberculosisQcrBrespiration
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.